NEW YORK (GenomeWeb) – Clearbridge Health subsidiary SAM Laboratory will be the exclusive provider of NanoString Technologies' Prosigna breast cancer prognostic gene signature assay to patients in Singapore, Malaysia, Indonesia, and the Philippines, Clearbridge said yesterday.

Under the terms of the agreement, Clearbridge will also distribute the assay on a non-exclusive basis throughout the rest of Asia, pending applicable local regulatory approvals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.